| Dr Ashley Caitlin Altman, MD | |
|
70 Doctors Park, Cape Girardeau, MO 63703-4928 | |
| (412) 999-5620 | |
| Not Available |
| Full Name | Dr Ashley Caitlin Altman |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 10 Years |
| Location | 70 Doctors Park, Cape Girardeau, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649697947 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 2021044487 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lourdes Hospital | Paducah, KY | Hospital |
| Massac Memorial Hospital | Metropolis, IL | Hospital |
| Anna Hospital Corporation D/b/a Union County Hospital | Anna, IL | Hospital |
| Franklin Hospital | Benton, IL | Hospital |
| Hamilton Memorial Hospital | Mcleansboro, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cape Radiology Group Pc | 9830093236 | 49 |
| Cape Radiology Group Pc | 9830093236 | 49 |
| Cape Radiology Group Pc | 9830093236 | 49 |
News Archive
There is no statistical evidence that global cigarette consumption has fallen as a result of the World Health Organization's Framework Convention on Tobacco Control, and in low- and middle-income countries it has actually increased, according to two studies led by global health researchers at York University.
Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.
Oncolytics Biotech Inc. announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
ECRI Institute Patient Safety Organization (PSO) today announces an agreement to provide patient safety services to the Tennessee Center for Patient Safety established by the Tennessee Hospital Association.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
› Verified 2 days ago
| Entity Name | University Of Chicago |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821048786 PECOS PAC ID: 7719899426 Enrollment ID: O20031103000094 |
News Archive
There is no statistical evidence that global cigarette consumption has fallen as a result of the World Health Organization's Framework Convention on Tobacco Control, and in low- and middle-income countries it has actually increased, according to two studies led by global health researchers at York University.
Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.
Oncolytics Biotech Inc. announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
ECRI Institute Patient Safety Organization (PSO) today announces an agreement to provide patient safety services to the Tennessee Center for Patient Safety established by the Tennessee Hospital Association.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
› Verified 2 days ago
| Entity Name | The University Of Chicago Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033218128 PECOS PAC ID: 7618880766 Enrollment ID: O20031106000203 |
News Archive
There is no statistical evidence that global cigarette consumption has fallen as a result of the World Health Organization's Framework Convention on Tobacco Control, and in low- and middle-income countries it has actually increased, according to two studies led by global health researchers at York University.
Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.
Oncolytics Biotech Inc. announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
ECRI Institute Patient Safety Organization (PSO) today announces an agreement to provide patient safety services to the Tennessee Center for Patient Safety established by the Tennessee Hospital Association.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
› Verified 2 days ago
| Entity Name | Suburban Radiologists, S.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386665396 PECOS PAC ID: 0648248328 Enrollment ID: O20040921000216 |
News Archive
There is no statistical evidence that global cigarette consumption has fallen as a result of the World Health Organization's Framework Convention on Tobacco Control, and in low- and middle-income countries it has actually increased, according to two studies led by global health researchers at York University.
Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.
Oncolytics Biotech Inc. announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
ECRI Institute Patient Safety Organization (PSO) today announces an agreement to provide patient safety services to the Tennessee Center for Patient Safety established by the Tennessee Hospital Association.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
› Verified 2 days ago
| Entity Name | Cape Radiology Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477506392 PECOS PAC ID: 9830093236 Enrollment ID: O20041011000076 |
News Archive
There is no statistical evidence that global cigarette consumption has fallen as a result of the World Health Organization's Framework Convention on Tobacco Control, and in low- and middle-income countries it has actually increased, according to two studies led by global health researchers at York University.
Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.
Oncolytics Biotech Inc. announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
ECRI Institute Patient Safety Organization (PSO) today announces an agreement to provide patient safety services to the Tennessee Center for Patient Safety established by the Tennessee Hospital Association.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
› Verified 2 days ago
| Entity Name | University Of Chicago |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477262046 PECOS PAC ID: 7719899426 Enrollment ID: O20230206002554 |
News Archive
There is no statistical evidence that global cigarette consumption has fallen as a result of the World Health Organization's Framework Convention on Tobacco Control, and in low- and middle-income countries it has actually increased, according to two studies led by global health researchers at York University.
Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.
Oncolytics Biotech Inc. announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
ECRI Institute Patient Safety Organization (PSO) today announces an agreement to provide patient safety services to the Tennessee Center for Patient Safety established by the Tennessee Hospital Association.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ashley Caitlin Altman, MD 70 Doctors Park, Cape Girardeau, MO 63703-4928 Ph: (573) 335-6671 | Dr Ashley Caitlin Altman, MD 70 Doctors Park, Cape Girardeau, MO 63703-4928 Ph: (412) 999-5620 |
News Archive
There is no statistical evidence that global cigarette consumption has fallen as a result of the World Health Organization's Framework Convention on Tobacco Control, and in low- and middle-income countries it has actually increased, according to two studies led by global health researchers at York University.
Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.
Oncolytics Biotech Inc. announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
ECRI Institute Patient Safety Organization (PSO) today announces an agreement to provide patient safety services to the Tennessee Center for Patient Safety established by the Tennessee Hospital Association.
Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.
› Verified 2 days ago
Karen B Willens, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 70 Doctors Park, Cape Girardeau, MO 63703 Phone: 573-335-6671 | |
Jeffrey William Boss, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 70 Doctors Park, Cape Girardeau, MO 63703 Phone: 573-334-6071 Fax: 573-334-4739 | |
Dr. Lance C. Faler, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 70 Doctors Park, Cape Girardeau, MO 63703 Phone: 573-334-6071 | |
Dr. Justin Ray Hodge, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 70 Doctor's Park, Cape Girardeau, MO 63703 Phone: 573-334-6071 Fax: 573-334-4739 | |
Abel Assefa Belay, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 70 Doctors Park, Cape Girardeau, MO 63703 Phone: 573-334-6071 | |
Yuan Yuan Xie, Radiology Medicare: Accepting Medicare Assignments Practice Location: 70 Doctors Park, Cape Girardeau, MO 63703 Phone: 573-334-6071 Fax: 573-334-4739 | |
Dr. George A. Pjura, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 70 Doctors Park, Cape Girardeau, MO 63703 Phone: 573-334-6071 Fax: 573-334-4739 |